Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Molecular Partners AG - American Depositary Shares (MOLN)
Company Research
Source: Yahoo! Finance
Full imaging and dosimetry data from MP0712 compassionate care program to be presented at TWC 2026 Phase 2 investigator-initiated trial of MP0317 now open with patient dosing ongoing, exploring MP0317 in combination with standard-of-care for patients with cholangiocarcinoma Phase 1/2a trial of multi-specific T cell engager MP0533 ongoing, update on clinical development path planned for H1 2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today provided an update on its latest progress, developments plans and expected 2026 milestones, which it will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California. “We are excited to have opened our Phase 1/2a trial in the US for MP0
Show less
Read more
Impact Snapshot
Event Time:
MOLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MOLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MOLN alerts
High impacting Molecular Partners AG - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MOLN
News
- Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics [Yahoo! Finance]Yahoo! Finance
- Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted RadiotherapeuticsGlobeNewswire
- Molecular Partners (NASDAQ:MOLN) had its price target lowered by analysts at JPMorgan Chase & Co. from $4.00 to $3.75. They now have a "neutral" rating on the stock.MarketBeat
MOLN
Analyst Actions
- 12/8/25 - JP Morgan
MOLN
Sec Filings
- 1/12/26 - Form 6-K
- 12/8/25 - Form 6-K
- 11/12/25 - Form 6-K
- MOLN's page on the SEC website